Stoke Therapeutics director acquires 61,750 shares via RSUs

Stoke Therapeutics director Edward M. Kaye, MD, increased his direct equity stake through RSU settlements.

Rhea-AI Filing Summary

Stoke Therapeutics director Edward M. Kaye, MD, increased his direct equity stake through RSU settlements. On March 15, 2026, he exercised or settled restricted stock units covering 61,750 shares of Common Stock at a stated price of $0.00 per share, reflecting equity compensation rather than open‑market purchases.

The RSU awards vest in annual installments of one quarter of the total shares beginning on March 15, 2024 and March 15, 2025, contingent on continued service. Following these transactions, Kaye directly holds 110,874 shares of Stoke Therapeutics Common Stock.

Insider Trade Summary

61,750 shares exercised/converted

Exercise 4 txns

Insider Kaye Edward M. MD

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	35,500	$0.00	$0.00
Exercise	Restricted Stock Units	26,250	$0.00	$0.00
Exercise	Common Stock	35,500	$0.00	$0.00
Exercise	Common Stock	26,250	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 88,000 contracts (Direct); Common Stock — 110,874 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
2. F2. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
3. F3. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Stoke Therapeutics (STOK) disclose for Edward M. Kaye, MD?

Stoke Therapeutics reported that director Edward M. Kaye, MD, exercised or settled restricted stock units into 61,750 shares of Common Stock on March 15, 2026. These equity awards are part of his compensation and do not represent open‑market share purchases or sales.

How many Stoke Therapeutics (STOK) shares does Edward M. Kaye hold after this Form 4?

After the March 15, 2026 transactions, Edward M. Kaye directly holds 110,874 shares of Stoke Therapeutics Common Stock. This total reflects the addition of 61,750 shares received through the exercise or settlement of restricted stock units granted as equity compensation.

Were the Stoke Therapeutics (STOK) insider transactions open‑market buys or sells?

The reported transactions were exercises or settlements of restricted stock units at a stated price of $0.00 per share, not open‑market buys or sells. They represent the conversion of previously granted equity compensation into Common Stock, with no sale volume disclosed in this filing.

What type of equity awards did Edward M. Kaye receive from Stoke Therapeutics (STOK)?

Edward M. Kaye holds restricted stock units, each representing a contingent right to receive one share of Common Stock upon settlement. The awards vest in four equal annual installments beginning March 15, 2024 and March 15, 2025, subject to his continued service with Stoke Therapeutics.

How many restricted stock units did Edward M. Kaye settle into Stoke Therapeutics (STOK) shares?

He settled restricted stock units relating to 61,750 shares of Stoke Therapeutics Common Stock on March 15, 2026. This consists of 35,500 underlying shares from one RSU award and 26,250 underlying shares from a second RSU award, both converted at a stated price of $0.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		35,500	A	$0	84,624	D
Common Stock	03/15/2026		M		26,250	A	$0	110,874	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/15/2026		M			35,500	(2)	03/15/2027	Common Stock	35,500	$0	35,500	D
Restricted Stock Units	(1)	03/15/2026		M			26,250	(3)	03/15/2028	Common Stock	26,250	$0	52,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

2. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.

3. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.